old wooden lungs were used in the 40's
Remembering the 'wooden lung': A retired respiratory therapist gave an educational presentation in Ishpeming Sunday on the Upper Peninsula polio outbreak of 1940
Tuesday, September 20, 2011
Thursday, September 15, 2011
BREATHE ARIZONA! FREEDOM FROM SMOKING!
FREEDOM FROM SMOKING
Did you know:
Cigarette smoking is the number one cause of preventable disease and death worldwide and smoking-related diseases claim over 393,000 American lives each year?
Smoking cost the United States over $193 billion in 2004, including $97 billion in lost productivity and $96 billion in direct health care expenditures, or an average of $4,260 per adult smoker?
If these statistics affect you or your workplace then you need to know more about the American Lung Association’s gold standard program, Freedom From Smoking®. Arizona is now offering Freedom From Smoking® in a variety of formats:
Freedom From Smoking® Online*, or FFS Online, is a program specifically designed for adults who want to quit smoking. It is accessible day or night, seven days a week, and has a series of lessons and modules to follow, many of which also come with an assignment.
Freedom From Smoking® In-Person Clinic* delivered by the American Lung Association provides a trained and certified Freedom From Smoking® facilitator who will implement the eight week course at your location and work with your audience to become smoke free. The facilitator will also coordinate the logistics of the clinics on your behalf.
Freedom From Smoking® Workplace Wellness* is delivered by your organization which allows you to send representatives to the certified facilitator training and become equipped to implement the 8 week course at any time you need it. The facilitator and workplace receive a certification that is good for three years.
UPCOMING FACILITATOR TRAINING*! SIGN UP TODAY!
October 26th & 27th (1 ½ days)
102 W. McDowell Rd.
Phoenix, AZ 85003
Register at 602-429-0009 or smortenson@Lungarizona.org.
Did you know:
Cigarette smoking is the number one cause of preventable disease and death worldwide and smoking-related diseases claim over 393,000 American lives each year?
Smoking cost the United States over $193 billion in 2004, including $97 billion in lost productivity and $96 billion in direct health care expenditures, or an average of $4,260 per adult smoker?
If these statistics affect you or your workplace then you need to know more about the American Lung Association’s gold standard program, Freedom From Smoking®. Arizona is now offering Freedom From Smoking® in a variety of formats:
Freedom From Smoking® Online*, or FFS Online, is a program specifically designed for adults who want to quit smoking. It is accessible day or night, seven days a week, and has a series of lessons and modules to follow, many of which also come with an assignment.
Freedom From Smoking® In-Person Clinic* delivered by the American Lung Association provides a trained and certified Freedom From Smoking® facilitator who will implement the eight week course at your location and work with your audience to become smoke free. The facilitator will also coordinate the logistics of the clinics on your behalf.
Freedom From Smoking® Workplace Wellness* is delivered by your organization which allows you to send representatives to the certified facilitator training and become equipped to implement the 8 week course at any time you need it. The facilitator and workplace receive a certification that is good for three years.
UPCOMING FACILITATOR TRAINING*! SIGN UP TODAY!
October 26th & 27th (1 ½ days)
102 W. McDowell Rd.
Phoenix, AZ 85003
Register at 602-429-0009 or smortenson@Lungarizona.org.
artificial airway implaned
MIT bioengineer to share medical prize
Robert Langer, the prolific MIT bioengineer whose work on tissue engineering and drug delivery has spawned many patents and local companies, will share the $250,000 Warren Alpert Foundation Prize, for contributions in biomedical research.
Carpentier successfully implanted an artificial airway to save the lung of a cancer patient.
Langer, who has built blood vessels from scratch and helped create an implantable wafer to deliver chemotherapy in the brain, shares the award with Alain Carpentier, a cardiovascular surgeon at the Hopital Européen Georges Pompidou in Paris. Carpentier successfully implanted an artificial airway to save the lung of a cancer patient.
The prize was created by Warren Alpert, a philanthropist dedicated to research that improves human health. Winners are selected by a scientific advisory board, which is chaired by Jeffrey S. Flier, the dean of Harvard Medical School.
It’s just the latest honor for Langer, who earlier this summer won the Priestley Medal, a top honor in chemistry.
By Carolyn Y. Johnson, Globe Staff
click to read the complete article on this transplant
http://www.boston.com/Boston/whitecoatnotes/2011/09/mit-bioengineer-share-medical-prize/OvPCGN5xLSrvKwMEfYBb1J/index.html
Robert Langer, the prolific MIT bioengineer whose work on tissue engineering and drug delivery has spawned many patents and local companies, will share the $250,000 Warren Alpert Foundation Prize, for contributions in biomedical research.
Carpentier successfully implanted an artificial airway to save the lung of a cancer patient.
Langer, who has built blood vessels from scratch and helped create an implantable wafer to deliver chemotherapy in the brain, shares the award with Alain Carpentier, a cardiovascular surgeon at the Hopital Européen Georges Pompidou in Paris. Carpentier successfully implanted an artificial airway to save the lung of a cancer patient.
The prize was created by Warren Alpert, a philanthropist dedicated to research that improves human health. Winners are selected by a scientific advisory board, which is chaired by Jeffrey S. Flier, the dean of Harvard Medical School.
It’s just the latest honor for Langer, who earlier this summer won the Priestley Medal, a top honor in chemistry.
By Carolyn Y. Johnson, Globe Staff
click to read the complete article on this transplant
http://www.boston.com/Boston/whitecoatnotes/2011/09/mit-bioengineer-share-medical-prize/OvPCGN5xLSrvKwMEfYBb1J/index.html
Friday, August 12, 2011
artificial organs are being developed
artificial organs are being developed
How advanced are other artificial parts?
A good demonstration of the power of protheses is on display in the lower limbs of Oscar Pistorius, the South African sprinter who has just run 400 metres fast enough to qualify for the 2012 Olympics. "Blade Runner", as Pistorius is known, has no legs from mid-calf down, and runs on carbon-fibre blades. His prosthetic legs were ruled to be acceptable for general competition by the IAAF, which said the legs did not give him an unfair advantage.
In medicine, prosthetic hearts have led the way for decades, although other artificial organs are being developed. A medical device firm called MC3 is currently testing a total artificial lung for submission to the Food and Drug Administration in the US. The device is designed to replace carbon dioxide in the blood with oxygen, using the heart's own pumping power.
Artificial livers are in the pipeline, too, although the technical challenges behind creating a whole, mechanical organ mean that most progress has come through growing liver tissue in the lab. Any artificial lung or liver currently in development is designed to be a "bridge to transplant".
click to see the complete article on artificial organs by Hal Hodson
How advanced are other artificial parts?
A good demonstration of the power of protheses is on display in the lower limbs of Oscar Pistorius, the South African sprinter who has just run 400 metres fast enough to qualify for the 2012 Olympics. "Blade Runner", as Pistorius is known, has no legs from mid-calf down, and runs on carbon-fibre blades. His prosthetic legs were ruled to be acceptable for general competition by the IAAF, which said the legs did not give him an unfair advantage.
In medicine, prosthetic hearts have led the way for decades, although other artificial organs are being developed. A medical device firm called MC3 is currently testing a total artificial lung for submission to the Food and Drug Administration in the US. The device is designed to replace carbon dioxide in the blood with oxygen, using the heart's own pumping power.
Artificial livers are in the pipeline, too, although the technical challenges behind creating a whole, mechanical organ mean that most progress has come through growing liver tissue in the lab. Any artificial lung or liver currently in development is designed to be a "bridge to transplant".
click to see the complete article on artificial organs by Hal Hodson
Video: Artificial Lung May Save Lives During Surgeries
Artificial Lung May Save Lives During Surgeries
Dr. Jeffrey Borenstein, principal investigator for tissue engineering at the Draper Labs, discusses a 1/100 scale prototype of an artificial lung under development by the Center for Integration of Medicine & Innovative Technology.
click to watch a brief video of this artificial ling
http://www.designnews.com/video.asp?section_id=1375&doc_id=
MEMS-Enabled Artificial Lung
MEMS-Enabled Artificial Lung
In a pioneering approach to artificial organ development, engineers at Draper Laboratory in Cambridge, Mass., are applying semiconductor manufacturing technology to the development of artificial organs such as lungs and kidneys.
Intricate internal structures produced via micro-electromechanical systems (MEMS) are being tested as vascular systems that could oxygenate a person's blood during surgery. They also could function down the road as part of an implantable device.
"This is important because oxygenators currently used during heart surgery use a significant amount of anticoagulants," says Dr. Jeffrey Borenstein, principal investigator in the tissue engineering research being conducted at Draper.
Most artificial lung devices used today consist of hollow, porous fiber bundles inside a hard-shelled jacket. Oxygen is introduced through the fibers and diffused into blood flowing around the fibers. This process often damages the blood for maximum membrane exposure.
Adverse interactions between the blood and device materials such as polyethersulfone may cause clotting. Preventing this requires a high level of anticoagulants, which can cause excessive bleeding and other problems for the patient.
Doctors at leading Boston teaching hospitals approached Borenstein and asked if Draper could research technologies to replace current oxygenating devices. The doctors were part of CIMIT, the Center for Integration of Medicine and Innovative Technology.
The idea was that microfabrication technology developed at Draper for sensors used in defense, aerospace, and commercial products such as digital cameras and the Nintendo Wii game controller might help create an artificial lung with microchannels that mimic the blood vessels in human organs.
The blood-side passages in current hollow fiber lung devices are 200-300 microns in diameter, compared with the 5-10 microns for a capillary. MEMS technology allows the creation of channels that are closer in size to the blood vessels found naturally in organs.
The result of Draper's work is a 1/100 scale prototype device that functions like a human lung. Blood enters and is infiltrated with oxygen in a microvascular network before exiting.
The basic techniques borrowed from semiconductor manufacturing are deposition of material layers, patterning by photolithography, and etching to produce the required shapes. "That's basically a planar process. The two big challenges we had were transferring from two-dimensional to three-dimensional and from inorganic silicon to medical-grade polymers," Borenstein says.
His team is using structures made of silicone rubber in the current prototype. They provide the mechanical strength and flexibility required for the device.
To become implantable, the device would need bioresorbable materials. Those materials would be engineered into a tissue scaffold, which would be seeded with a person's own stem cells and grown into a kidney, a lung, or some other organ. The bioresorbable polymer would disappear after the structure was formed.
Borenstein's work is important in the field of tissue engineering because larger organs such as kidneys and livers require intensive internal vascular structures. But that stage is well down the road.
"Our work has been funded by the National Institutes of Health, and for the next phase of development [a device used outside the human body], we are looking for commercial partners," he says. Completion of that phase is very feasible within the next several years, in Borenstein's view.
Other research groups around the world are focusing on other aspects of developing artificial lungs. For example, researchers in Cleveland have developed a prototype artificial lung that functions with air, just like human lungs.
Charles Stark Draper, an aeronautics professor at the Massachusetts Institute of Technology, formed a lab in the late 1930s to develop instruments to measure aircraft motion. The lab was later named after Draper, and its work advanced to include missile guidance systems, space exploration, advance robotic technologies, and tissue engineering. The lab was spun out of MIT in 1973.
http://www.designnews.com/document.asp?doc_id=232240&f_src=designnews_gnews
click to see a short video amd more info on this approach for a artificial lung
In a pioneering approach to artificial organ development, engineers at Draper Laboratory in Cambridge, Mass., are applying semiconductor manufacturing technology to the development of artificial organs such as lungs and kidneys.
Intricate internal structures produced via micro-electromechanical systems (MEMS) are being tested as vascular systems that could oxygenate a person's blood during surgery. They also could function down the road as part of an implantable device.
"This is important because oxygenators currently used during heart surgery use a significant amount of anticoagulants," says Dr. Jeffrey Borenstein, principal investigator in the tissue engineering research being conducted at Draper.
Most artificial lung devices used today consist of hollow, porous fiber bundles inside a hard-shelled jacket. Oxygen is introduced through the fibers and diffused into blood flowing around the fibers. This process often damages the blood for maximum membrane exposure.
Adverse interactions between the blood and device materials such as polyethersulfone may cause clotting. Preventing this requires a high level of anticoagulants, which can cause excessive bleeding and other problems for the patient.
Doctors at leading Boston teaching hospitals approached Borenstein and asked if Draper could research technologies to replace current oxygenating devices. The doctors were part of CIMIT, the Center for Integration of Medicine and Innovative Technology.
The idea was that microfabrication technology developed at Draper for sensors used in defense, aerospace, and commercial products such as digital cameras and the Nintendo Wii game controller might help create an artificial lung with microchannels that mimic the blood vessels in human organs.
The blood-side passages in current hollow fiber lung devices are 200-300 microns in diameter, compared with the 5-10 microns for a capillary. MEMS technology allows the creation of channels that are closer in size to the blood vessels found naturally in organs.
The result of Draper's work is a 1/100 scale prototype device that functions like a human lung. Blood enters and is infiltrated with oxygen in a microvascular network before exiting.
The basic techniques borrowed from semiconductor manufacturing are deposition of material layers, patterning by photolithography, and etching to produce the required shapes. "That's basically a planar process. The two big challenges we had were transferring from two-dimensional to three-dimensional and from inorganic silicon to medical-grade polymers," Borenstein says.
His team is using structures made of silicone rubber in the current prototype. They provide the mechanical strength and flexibility required for the device.
To become implantable, the device would need bioresorbable materials. Those materials would be engineered into a tissue scaffold, which would be seeded with a person's own stem cells and grown into a kidney, a lung, or some other organ. The bioresorbable polymer would disappear after the structure was formed.
Borenstein's work is important in the field of tissue engineering because larger organs such as kidneys and livers require intensive internal vascular structures. But that stage is well down the road.
"Our work has been funded by the National Institutes of Health, and for the next phase of development [a device used outside the human body], we are looking for commercial partners," he says. Completion of that phase is very feasible within the next several years, in Borenstein's view.
Other research groups around the world are focusing on other aspects of developing artificial lungs. For example, researchers in Cleveland have developed a prototype artificial lung that functions with air, just like human lungs.
Charles Stark Draper, an aeronautics professor at the Massachusetts Institute of Technology, formed a lab in the late 1930s to develop instruments to measure aircraft motion. The lab was later named after Draper, and its work advanced to include missile guidance systems, space exploration, advance robotic technologies, and tissue engineering. The lab was spun out of MIT in 1973.
http://www.designnews.com/document.asp?doc_id=232240&f_src=designnews_gnews
click to see a short video amd more info on this approach for a artificial lung
Tuesday, August 9, 2011
new research in intelligent artificial lungs
Welsh government funds new research in intelligent artificial lungs
Swansea University is looking to develop the world's first intelligent artificial lung, thanks to new government funding.
The device is scheduled for clinical trials in two years and will allow those with low breathing functions and lung diseases to breathe properly and comfortably.
Swansea University is looking to develop the world's first intelligent artificial lung, thanks to new government funding.
The device is scheduled for clinical trials in two years and will allow those with low breathing functions and lung diseases to breathe properly and comfortably.
Subscribe to:
Posts (Atom)